Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy.

British journal of cancer - 1 Jul 2018

Dupuis Frantz, Lamant Laurence, Gerard Emilie, Torossian Nouritza, Chaltiel Leonor, Filleron Thomas, Beylot-Barry Marie, Dutriaux Caroline, Prey Sorilla, Gros Audrey, Jullie Marie-Laure, Meyer Nicolas, Vergier Béatrice

Abstract excerpt

BACKGROUND: Prescribing anti-programmed death-1 (PD-1) immunotherapy for advanced melanoma is currently not restricted by any biomarker assessment. Determination of programmed death-ligand-1 (PD-L1)-expression status is technically challenging and is not mandatory, because negative tumours also achieve therapeutic responses. However, reproducible biomarkers predictive of a response to anti-PD-1 therapy could...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Differentiation, Myelomonocytic
Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CD163 Antigen

Share to GTP Phosphohydrolases

Share to Immunotherapy

Share to Neoplasms, Second Primary

Share to Programmed Cell Death 1 Receptor

Share to Progression-Free Survival

Source

Open in PubMed Open full text

Identifiers

PMID: 29973670
DOI: 10.1038/s41416-018-0168-9
PMCID: PMC6048096

Genes

NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy.PMID 29973670Read ↗

Baseline tumor-infiltrating lymphocyte patterns and response to immune checkpoint inhibition in metastatic cutaneous melanomaSemantic proximity Read ↗

Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma.Semantic proximity Read ↗

The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitorsSemantic proximity Read ↗

Programmed Cell Death Ligand 1 Immunohistochemical Expression and Cutaneous Melanoma: A Controversial RelationshipSemantic proximity Read ↗

Improving melanoma classification by integrating genetic and morphologic features.Semantic proximity Read ↗

TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy.Semantic proximity Read ↗

Melanoma: Prognostic Factors and Factors Predictive of Response to Therapy.Semantic proximity Read ↗

Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma.Semantic proximity Read ↗

Prognostic signs in melanoma: state of the art.Semantic proximity Read ↗

Correlation of MET and PD-L1 expression in malignant melanomaSemantic proximity Read ↗

Adjuvant treatment with anti-PD-1 in acral melanoma: A nationwide study.Semantic proximity Read ↗

Prognostic Clinical and Radiographic Biomarkers for BRAF-Targeted Therapy in Advanced Melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.